SAB Biotherapeutics Inc (SABS NASDAQ) stock market data APIs
$3.8311
0.13(3.4%)
as of July 10, 2026
Try our APIs with
free plan!
SAB Biotherapeutics Inc Financial Data Overview
Price chart is built with
Anychart
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Prev. Close
3.8311
Open
3.9625
High
3.9728
Low
3.743
52 wk Range
1.85-5.15
Market Cap
292 M
Shares Outstanding
76 464 K
Revenue
115 K
EPS
-0.3523
Beta
0.53
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with SAB Biotherapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SAB Biotherapeutics Inc data using free add-ons & libraries
Get SAB Biotherapeutics Inc Fundamental Data
SAB Biotherapeutics Inc Fundamental data includes:
- Net Revenue: 115 K
- EBITDA: -55 123 040
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-12
- EPS/Forecast: -0.208
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SAB Biotherapeutics Inc News
New
Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?
SAB Biotherapeutics, Inc. (NASDAQ:SABS) ranks among the overlooked penny stocks to buy right now, supported by strong upside potential. Back-to-back bullish analyst calls are pointing to a wide gap be...
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)
SAB Biotherapeutics Inc. (NASDAQ:SABS) is one of the 10 best stocks under $10 offering more than 50% upside. On June 24, Eliana Merle from Barclays initiated coverage of SAB Biotherapeutics Inc. (NAS...
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
MIAMI, May 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1...
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Emergent BioSolutions Inc. (NYSE:EBS) is one of the best pharmaceutical stocks to invest in. TheFly reported on Ap...
Get SAB Biotherapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
